

Clinical Trial Protocol

Iranian Registry of Clinical Trials

13 Jun 2026

The effectiveness of neurofeedback on the severity of gastrointestinal symptoms, depression, anxiety, stress and quality of life in patients with irritable bowel syndrome (IBS)

Protocol summary

Study aim

Determining the effectiveness of neurofeedback on the severity of gastrointestinal symptoms, Depression, Anxiety, Stress and Quality of life in patients with irritable bowel syndrome.

Design

Clinical trial with double-blind, randomized, and parallel group design of 45 patients, random allocation rule type is used by lottery balls.

Settings and conduct

Clinical trial is performed in the Clinic of Gastrointestinal Functional Disorders with randomized double blind parallel groups. patients are not aware of the treatment of other group, Therapists are unaware of other groups treatment and assessment, and evaluators are unaware group types . patients are assessed by assessors for quality of life , IBS symptom severity, anxiety and depression. At the end of the course, all groups will be assessed .

Participants/Inclusion and exclusion criteria

Inclusion criteria :Having diagnostic full criteria of IBS based on Rome III criteria, age between 18 to 45 years.
Non-inclusion criteria: dissatisfaction to participate , having bloody stools, family history of colon cancer, Unstable weight loss, anemia and eosinophilia, rectosigmoid, abnormal scoping, and concomitant psychiatric and neurological diseases

Intervention groups

For the intervention group, neurofeedback method from the unipolar protocol of anxiety on the PZ point and for depression at point F3 will be done .for placebo group, the Active Electrodes are placed in the middle of the skull at point CZ and the Grand Electrode is attached to the softness of the patient's ear. The control group receives only routine gastrointestinal drug treatment.

Main outcome variables

Reduce the severity of gastrointestinal symptoms,

reduce depression, anxiety, stress and increase quality of life In patients with irritable bowel syndrome.

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20191215045743N1**

Registration date: **2020-12-23, 1399/10/03**

Registration timing: **retrospective**

Last update: **2020-12-23, 1399/10/03**

Update count: **0**

Registration date

2020-12-23, 1399/10/03

Registrant information

Name

Saeid Nasiri Dehsorkhi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 31 3660 1851

Email address

s.nasiri.isf@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-11-10, 1399/08/20

Expected recruitment end date

2020-11-15, 1399/08/25

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date
empty

Scientific title
The effectiveness of neurofeedback on the severity of gastrointestinal symptoms, depression, anxiety, stress and quality of life in patients with irritable bowel syndrome (IBS)

Public title
Evaluation of the effectiveness of neurofeedback on irritable bowel syndrome

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria:
Having diagnostic criteria for IBS based on Rome III criteria , all three types of IBS included: C, D and M kind age between 18 and 45 years education: at least second level at middle school degree
Exclusion criteria:
patients who refused to participate in study positive Family history of colon cancer WBC, parasites and blood in the stool History of thyroid disorders and abnormal thyroid test, Patients with unstable weight loss, anemia and eosinophilia, rectosigmoid and abnormal scoping Having diagnostic Criteria of Severe psychiatric and neurological disorders based on psychiatrist diagnosis. Having bloody stools

Age
From **18 years** old to **45 years** old

Gender
Both

Phase
N/A

Groups that have been masked

- Participant
- Care provider
- Outcome assessor

Sample size
Target sample size: **45**

Randomization (investigator's opinion)
Randomized

Randomization description
Eligible participants include 45 people who are randomly assigned to three groups. Our method of randomization will be Random allocation rule that is a simple way of randomization. The randomization unit is the patient who is assigned to one of the groups A, B and C by the law of random allocation. In this way, the code of each person is recorded inside a lottery ball and is randomly removed from the container without any replacement and the created sequence is created. In this process, the person who assigns patients to the groups is not aware of the type of treatment groups. and does not know what intervention the next group is related to.

Blinding (investigator's opinion)
Double blinded

Blinding description
In this study, those who randomly assign participants to

treatment groups do not know the nature of the groups. Therapists are also unaware of the type of treatment of other groups. Evaluators are also unaware of the type of groups.

Placebo
Used

Assignment
Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Isfahan University of medical Sciences

Street address

Hezarjirib,Isfahan University of Medical Sciences

City

ISFAHAN

Province

Isfahan

Postal code

7346181746

Approval date

2020-11-04, 1399/08/14

Ethics committee reference number

IR.MUI.REC.1396.2.129

Health conditions studied

1

Description of health condition studied

Irritable Bowel Syndrom

ICD-10 code

K58

ICD-10 code description

Irritable bowel syndrome

Primary outcomes

1

Description

Severity of gastrointestinal symptoms of irritable bowel syndrome based on IBS Symptom Severity Questionnaire,Symptoms of depression, anxiety and stress based on the score in DASS-42,Quality of life based on score in IBS-QOL-34 questionnaire

Timepoint

Before the intervention, the severity of gastrointestinal symptoms, depression, anxiety, stress and quality of life are measured. The list of alpha and beta waves is saved after each session. At the end of the sessions, the rate of gastrointestinal symptoms, psychological symptoms and

quality of life are measured.

Method of measurement

IBS-SSS Intensity of Gastrointestinal Symptoms Questionnaire, DASS-42 Questionnaire - Quality of Life Assessment QOL-34. Record brain waves of alpha and beta waves.

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: Neurofeedback:For the intervention group, the neurofeedback method is performed from the unipolar protocol of anxiety at point PZ and for the treatment of depression at point F3. Treatment plan include 20 sessions which is done three times a week.

Category

Treatment - Other

2

Description

Intervention group: Placebo (quasi-neurofeedback): for the placebo control group where the Active Electrodes are placed in the middle of the skull at point CZ and the Grand Electrode is attached to the softness of the patient's ear.similar to intervention group, placebo Treatment plan include 20 sessions which is done three times a week.

Category

Placebo

3

Description

Control group: Routine gastrointestinal medications:This group receives only routine gastrointestinal medication according to the opinion of the gastroenterologist. Simultaneous evaluation is performed before and after the intervention of the intervention groups.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Psychosomatic Research Center

Full name of responsible person

Dr. Amrolah Ebrahime

Street address

Psychosomatic Research Center, West Shariati street,Isfahan, Iran -

City

Isfahan

Province

Isfahan

Postal code

8173948763

Phone

+98 31 3628 9966

Email

psrc@mui.ac.ir

Web page address

https://psrc.mun.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Dr. Amrolah Ebrahime

Street address

Isfahan University of Medical Sciences, Hezar Jarib Street, Azadi Square, Isfahan

City

Isfahan

Province

Isfahan

Postal code

81746-73461

Phone

+98 31 3668 0048

Email

researchmanager@mui.ac.ir

Web page address

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Esfahan University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Amrollah Ebrahimi

Position

Associate professor

Latest degree

Ph.D.

Other areas of specialty/work

Psychology

Street address

Department of Health Psychology, Medicine School,
Isfahan University of Medical Sciences, Hezarjirib
Street

City

Isfahan

Province

Isfahan

Postal code

8174673461

Phone

+98 31 3668 9313

Email

a_ebrahimi@med.mui.ac.ir

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Esfahan University of Medical Sciences

Full name of responsible person

Amrollah Ebrahimi

Position

Associate Professor, Department of Health
Psychology, Isfahan University of Medical Sciences

Latest degree

Ph.D.

Other areas of specialty/work

Psychology

Street address

Unit 5, Niloufar Building, Varpshiti Alley, Sharafuddin
Alley West Shariati Street, Hakim Nezami Avenue

City

Isfahan

Province

Isfahan

Postal code

8173955174

Phone

+98 31 3625 8818

Email

amrollahebi@gmail.com

Person responsible for updating data**Contact****Name of organization / entity**

Esfahan University of Medical Sciences

Full name of responsible person

Amrollah Ebrahimi

Position

Associate professor

Latest degree

Ph.D.

Other areas of specialty/work

Psychology

Street address

NO16, Sharafodin Avne, West Shariati Street

City

Isfahan

Province

Isfahan

Postal code

8173955174

Phone

+98 31 6258818

Email

a_ebrahimi@med.mui.ac.ir

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

Not applicable

Title and more details about the data/document

Findings and data including the severity of
gastrointestinal symptoms, anxiety, depression, stress
and quality of life before and after the intervention can
be shared.

When the data will become available and for how long

Access starts 4 months after the article is published

To whom data/document is available

Data and documentation are available to academic
researchers and medical staff.

Under which criteria data/document could be used

Citing the source and preserving the rights of the
researchers in this study

From where data/document is obtainable

Refer to the Vice Chancellor for Research, Isfahan
University of Medical Sciences

What processes are involved for a request to access data/document

The applicant can write a letter to the Vice Chancellor for
Research of Isfahan University of Medical Sciences and
request to receive the file. With the coordination of the
executors, the files will be provided to the applicant

Comments